June 1, 2009 - Generex Biotechnology Corporation announced today that the results of a recently completed Phase I trial in prostate cancer patients of the novel immunotherapeutic peptide AE37 were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Fla., from May 29 to June 2, 2009.
The studies were conducted in Athens, Greece under the direction of medical doctor Constantin Baxevanis. The immunotherapeutic peptide AE37 is being developed by Antigen Express Inc., a wholly-owned subsidiary of Generex, for multiple cancer indications.
The study, entitled "Results from the First Phase I Clinical Study of the Novel Ii-Key/HER-2/neu (776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer," reports on both the safety and immunological response to the vaccine in patients. The trial demonstrated that the vaccine is safe, well tolerated and produces the desired immunological response in patients. The results of this study are consistent with those of prior clinical trials of AE37 in patients with breast cancer. AE37 is currently the subject of a randomized phase II clinical trial in patients with node positive or high risk node negative breast cancer as well as an additional phase I trial wherein it is being studied in combination with another immunotherapeutic peptide.
For more information: www.generex.com
October 30, 2026 
